Philip M. Arlen

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein et al. · Journal of Clinical Oncology · 2010 · 973 citations

Medicine, Immunology, Oncology +17

Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

James L. Gulley, Philip M. Arlen, Anne Bastian et al. · Clinical Cancer Research · 2005 · 371 citations

Medicine, Oncology, Radiation Oncology +17

Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

John L. Marshall, Robert J. Hoyer, Mary Ann Toomey et al. · Journal of Clinical Oncology · 2000 · 357 citations

Medicine, Immunology, Oncology +17

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

William L. Dahut, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2004 · 350 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Ravi A. Madan, Mahsa Mohebtash, Philip M. Arlen et al. · The Lancet Oncology · 2012 · 327 citations · Full text

Medicine, Immunology, Oncology +17